0001171843-17-004625.txt : 20170802
0001171843-17-004625.hdr.sgml : 20170802
20170802170154
ACCESSION NUMBER: 0001171843-17-004625
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170728
FILED AS OF DATE: 20170802
DATE AS OF CHANGE: 20170802
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GOLDENBERG DAVID M
CENTRAL INDEX KEY: 0001029578
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-12104
FILM NUMBER: 171001014
MAIL ADDRESS:
STREET 1: UBS GLOBAL ASSET MANAGEMENT (US) INC.
STREET 2: 51 WEST 52ND STREET
CITY: NEW YORK
STATE: NY
ZIP: 10019
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IMMUNOMEDICS INC
CENTRAL INDEX KEY: 0000722830
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 611009366
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 300 AMERICAN RD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
BUSINESS PHONE: 9736058200
MAIL ADDRESS:
STREET 1: 300 AMERICAN ROAD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
4
1
f4_dgoldenberg080217.xml
OWNERSHIP DOCUMENT
X0306
4
2017-07-28
0
0000722830
IMMUNOMEDICS INC
IMMU
0001029578
GOLDENBERG DAVID M
C/O IMMUNOMEDICS, INC
300 THE AMERICAN ROAD
MORRIS PLAINS
NJ
07950
1
1
0
0
See Remarks
Common Stock
2017-07-28
4
A
0
4874
0
A
2405928
D
Common Stock
2017-07-28
4
F
0
1950
8.75
D
2403978
D
Common Stock
2017-07-28
4
A
0
4873
0
A
3472296
I
See Footnote
Represents the settlement of common stock underlying Performance Units that have vested in accordance with the terms of the Performance-Based Restricted Stock Unit Agreement entered into on August 16, 2013 by and between the Company and each of the reporting person and his spouse, Ms. Cynthia L. Goldenberg, a director of the Company.
Includes a total of 190,000 shares held as joint tenants by the reporting person and Ms. Goldenberg.
Such shares are held by the reporting person's spouse, by various trusts established for the benefit of the reporting person and/or family members of the reporting person, or by a majority-owned subsidiary of the Issuer, of which the reporting person is an officer. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interests therein.
Chief Scientific Officer and Chief Patent Officer
/s/ Cynthia L. Sullivan, Attorney-In-Fact
2017-08-02